Favorable Press Coverage Somewhat Unlikely to Affect iShares Nasdaq Biotechnology Index Fund (IBB) Share Price
Media coverage about iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) has trended positive on Sunday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. iShares Nasdaq Biotechnology Index Fund earned a news impact score of 0.27 on Accern’s scale. Accern also assigned media stories about the financial services provider an impact score of 46.109097306948 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) traded up $0.45 during trading hours on Friday, hitting $105.70. The company had a trading volume of 2,822,782 shares, compared to its average volume of 2,634,333. iShares Nasdaq Biotechnology Index Fund has a twelve month low of $87.22 and a twelve month high of $114.17.
About iShares Nasdaq Biotechnology Index Fund
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Receive News & Ratings for iShares Nasdaq Biotechnology Index Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology Index Fund and related companies with Analyst Ratings Network's FREE daily email newsletter.